SYMBRAVO, which combines meloxicam and rizatriptan, targets multiple pathways underlying a migraine attack. Clinical trials have shown that a single dose can provide rapid pain relief and return ...

The adjustment follows the recent approval of Axsome's migraine treatment, Symbravo (AXS-07), which has been met with positive reception and is predicted to have a strong commercial future.

Axsome Therapeutics (AXSM) announced that the EMERGE Phase 3 trial of SYMBRAVO in patients experiencing inadequate response to oral CGRP inhibitors met its primary endpoint, with SYMBRAVO ...

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults.

Findings showed meloxicam/rizatriptan statistically significantly improved migraine treatment response compared with prior oral CGRP inhibitor treatment. Topline data were announced from a phase 3 ...

NEW YORK - Axsome Therapeutics, Inc. (NASDAQ: NASDAQ:AXSM), a biopharmaceutical company valued at $6.69 billion, announced today the successful results of their EMERGE Phase 3 trial for SYMBRAVO ...

On January 30, 2025, the U.S. Food and Drug Administration (FDA) approved Symbravo for the acute treatment of migraine with or without aura in adults. Symbravo represents a novel, multi ...

In January 2025, the FDA approved Axsome’s Symbravo (meloxicam and rizatriptan) or AXS-07 for the acute treatment of migraine with or without aura in adults. The company expects to launch ...

Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs Axsome's Symbravo outperformed oral CGRP inhibitors in a ...

NEW YORK - Axsome Therapeutics, Inc. (NASDAQ: NASDAQ:AXSM), a biopharmaceutical company valued at $6.69 billion, announced today the successful results of their EMERGE Phase 3 trial for SYMBRAVO®, a ...